Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma

THURSDAY, Sept. 7, 2023 -- The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study published in the Sept. 7 issue of the New England...